Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.05B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$636M |
| 4 |
TSMC
TSM
|
+$604M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.25B |
| 2 |
Apple
AAPL
|
+$1.13B |
| 3 |
Microsoft
MSFT
|
+$988M |
| 4 |
Meta Platforms (Facebook)
META
|
+$572M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$570M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.55% |
| 2 | Consumer Discretionary | 0.95% |
| 3 | Financials | 0.77% |
| 4 | Healthcare | 0.67% |
| 5 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MODV
12001
DELISTED
ModivCare
MODV
| $30.8K | ﹤0.01% |
23,426
+9,818
| +72% | +$47.5K |
|
12002
PDS Biotechnology
PDSB
$12.4M
| $30.6K | ﹤0.01% |
25,753
-221,224
| -90% | -$315K |
|
12003
PUT
E.W. Scripps
SSP
$305M
| $30.5K | ﹤0.01% |
+10,300
| New | +$22.5K |
|
|
GITS
12004
Global Interactive Technologies
GITS
$5.99M
| $30.5K | ﹤0.01% |
+24,976
| New | +$63.9K |
|
12005
CALL
Goldgroup Mining
GORO
$292M
| $30.4K | ﹤0.01% |
59,700
+31,600
| +112% | +$13.1K |
|
|
CLSD
12006
DELISTED
Clearside Biomedical
CLSD
| $30.4K | ﹤0.01% |
2,211
-1,725
| -44% | -$24.8K |
|
12007
CareCloud
CCLD
$102M
| $30.4K | ﹤0.01% |
21,853
+7,885
| +56% | +$23.2K |
|
12008
CALL
Kaixin Holdings
KXIN
$9.1M
| $30.3K | ﹤0.01% |
72
-16
| -18% | -$9.22K |
|
|
ENFY
12009
DELISTED
Enlightify Inc
ENFY
| $30.1K | ﹤0.01% |
+28,024
| New | +$31.9K |
|
12010
Tevogen Inc
TVGN
$45.4M
| $30.1K | ﹤0.01% |
+557
| New | +$36.6K |
|
12011
CALL
C4 Therapeutics
CCCC
$517M
| $30.1K | ﹤0.01% |
18,800
+900
| +5% | +$2.68K |
|
|
PRPH
12012
DELISTED
ProPhase Labs
PRPH
| $29.9K | ﹤0.01% |
7,401
+2,706
| +58% | +$12.4K |
|
12013
PUT
Aqua Metals
AQMS
$10.1M
| $29.9K | ﹤0.01% |
+1,600
| New | +$33K |
|
12014
AgEagle Aerial Systems
UAVS
$67.9M
| $29.9K | ﹤0.01% |
23,168
| – | – |
|
12015
Acrivon Therapeutics
ACRV
$93.4M
| $29.6K | ﹤0.01% |
+14,580
| New | +$78.5K |
|
12016
CALL
Valens Semiconductor
VLN
$196M
| $29.6K | ﹤0.01% |
+14,500
| New | +$36K |
|
|
DADA
12017
CALL
DELISTED
Dada Nexus
DADA
| $29.4K | ﹤0.01% |
+15,900
| New | +$27.4K |
|
12018
Usio Inc
USIO
$83.8M
| $29.3K | ﹤0.01% |
+20,083
| New | +$36.3K |
|
12019
Inuvo
INUV
$11.8M
| $29.3K | ﹤0.01% |
8,256
+5,335
| +183% | +$24.4K |
|
12020
CALL
Rani Therapeutics
RANI
$103M
| $29K | ﹤0.01% |
23,000
-17,700
| -43% | -$26.2K |
|
12021
SCYNEXIS
SCYX
$51.6M
| $29K | ﹤0.01% |
+3,803
| New | +$32.9K |
|
|
IGMS
12022
DELISTED
IGM Biosciences
IGMS
| $29K | ﹤0.01% |
25,180
-7,187
| -22% | -$13.4K |
|
|
HEPS
12023
CALL
D-Market Electronic Services & Trading
HEPS
$965M
| $28.8K | ﹤0.01% |
+10,100
| New | +$32.7K |
|
|
NXDR
12024
CALL
Nextdoor Holdings
NXDR
$925M
| $28.8K | ﹤0.01% |
18,800
-6,800
| -27% | -$15.2K |
|
12025
One Stop Systems
OSS
$277M
| $28.7K | ﹤0.01% |
12,385
+293
| +2% | +$981 |
|
Similar funds
Jeff Yass's Q1 2025 Portfolio in Review
As of Q1 2025, Jeff Yass held 13,842 positions worth $586B, down 12% from $663B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass withdrew a net $24.4B in Q1 2025, closing 1,482 positions and reducing 4,842 holdings. Its most notable exit was Inari Medical, Inc. Common Stock, an estimated $24M position sold in full.
By sector, the portfolio is most concentrated in Technology at 1.6% of assets, down from 2% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jeff Yass opened a new position in Brookfield Asset Management worth $86M.
- Jeff Yass's largest Q1 2025 buy was Brookfield Asset Management: 1,775,684 shares worth $86M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $4.05B increase.
- Jeff Yass's biggest Q1 2025 reduction was Invesco QQQ Trust, cutting an estimated $1.25B.
- Jeff Yass fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $24M.
- Jeff Yass's ten largest holdings make up 28% of its $586B portfolio in Q1 2025.
- Jeff Yass opened 1,775 new positions and closed 1,482 in Q1 2025.
- Jeff Yass's portfolio value fell 12% quarter-over-quarter to $586B.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.